Loading...
NPI 1346227048 · Hot Springs, AR · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Roy Webb is a hematology & oncology physician provider located in Hot Springs, Arkansas. This profile covers 68 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Roy Webb |
| Address | 133 Harmony Park |
| City | Hot Springs |
| State | AR |
| ZIP | 71913 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | December 23, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.9M |
| Medicaid | $210 |
This provider’s billing is overwhelmingly Medicare‑driven: total Medicare revenue is $1.9M versus total Medicaid revenue of $214, so the practice is effectively single‑payer with Medicare as the dominant commercial source of billed services. The tiny Medicaid tally indicates negligible participation or patient mix from that program relative to Medicare.
Medicare revenue is highly concentrated in a small set of therapies: the precomputed top three Medicare codes account for 71.1% of this provider’s total Medicare revenue. The single largest line item is J9271 ($756.8K; 40.9% of Medicare revenue), followed by J9299 ($368.6K; 19.9%) and 78815 ($189.9K; 10.3%), indicating most income derives from a few high‑value oncology services.
The code mix points to a specialty hematology/oncology practice focused on systemic immunotherapy and imaging support: substantial revenues from J9271 (pembrolizumab) and J9299 (nivolumab) indicate routine administration of checkpoint inhibitor therapy, while 78815 (PET/CT fusion imaging) at meaningful revenue supports staging and treatment monitoring tied to those therapies. Together these codes imply an outpatient infusion/oncology service line with integrated diagnostic imaging rather than a primarily procedural or surgical practice.
On national competitive standing for the top revenue drivers, this provider is a typical to modest participant: J9271 ranks #522 of 1841 providers (71st percentile) and is described as typical/unremarkable volume, J9299 ranks #239 of 505 (53rd percentile) and is likewise typical/unremarkable, while 78815 ranks #1076 of 6566 (84th percentile) and is reported as a typical, unremarkable volume. These ranks suggest the provider is not a dominant national center for these agents but maintains routine, established use consistent with community oncology patterns.
Several visit and infusion administration codes show comparatively high percentile placements that indicate steady outpatient throughput: 99213 is at the 98th percentile and labeled an "extreme outlier, far above typical national volume," 99214 is at the 96th percentile and labeled "notably above typical national volume," and 96413 is at the 95th percentile and labeled "notably above typical national volume." Additionally, 96372 is at the 98th percentile and described as "notably above typical national volume," while codes such as 96375 (95th percentile) are nonetheless described as typical/unremarkable. Collectively, these patterns point to above‑average E/M and infusion activity per provider relative to national peers.
Medicaid activity is minimal and highly concentrated: total Medicaid revenue is $214, with 85025 (CBC) accounting for $208 and therefore 100.0% of the provider’s Medicaid revenue per the precomputed top‑3 figure. That single test ranks #298 of 331 in‑state (9th percentile) and implies the provider is a low‑volume Medicaid participant for laboratory services compared with in‑state peers.
The provider has a long tenure in the NPI registry (enumerated on 2005-12-23, ~21 years ago), which supports interpretation of these patterns as stable practice behavior rather than a new or transient billing profile. Combined with the Medicare revenue scale and the focused code mix, the data are consistent with an established Hematology & Oncology physician operating an outpatient infusion/oncology service line with limited Medicaid caseload.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
68 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 17,600 | $40 | $756.8K |
| J9299 | Injection, nivolumab, 1 mg | 15,360 | $20 | $368.6K |
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 190 | $990 | $189.9K |
| J0897 | Injection, denosumab, 1 mg | 5,400 | $20 | $97.2K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 790 | $90 | $67.5K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 880 | $60 | $53.7K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 620 | $90 | $53.3K |
| J1437 | Injection, ferric derisomaltose, 10 mg | 2,700 | $20 | $43.2K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 6,700 | $10 | $40.2K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 170 | $120 | $21.2K |
Showing 1–10 of 68
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 68 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
68 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 25 | 40 | 20,700 | $40 | $896.3K |
| J9299 | 17 | 30 | 15,660 | $20 | $432.9K |
| J1437 | 20 | 20 | 6,450 | $20 | $107.8K |
| J0897 | 49 | 160 | 2,580 | $20 | $89.7K |
| 78815 | 30 | 100 | 90 | $550 | $83.7K |
| J0885 | 15 | 40 | 4,070 | $10 | $38K |
| 96413 | 21 | 80 | 380 | $90 | $36.6K |
| A9552 | 17 | 40 | 180 | $150 | $28.9K |
| Q5122 | 5 | 10 | 250 | $90 | $24.9K |
| J9217 | 27 | 50 | 100 | $130 | $20K |
Showing 1–10 of 68
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 30 | $10 | $210 |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 30 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Arkansas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Arkansas median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 298 | 330 | 680 | $10 | $48.3K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 492 | 550 | 330 | $1 | $10K |
Other providers in the same ZIP code as Roy Webb, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.